Analysis of Intestinal Metaplasia Without Dysplasia in the Urinary Bladder Reveal Only Rare Mutations Associated With Colorectal Adenocarcinoma.


Journal

Applied immunohistochemistry & molecular morphology : AIMM
ISSN: 1533-4058
Titre abrégé: Appl Immunohistochem Mol Morphol
Pays: United States
ID NLM: 100888796

Informations de publication

Date de publication:
Historique:
pubmed: 27 12 2019
medline: 28 8 2021
entrez: 27 12 2019
Statut: ppublish

Résumé

Intestinal metaplasia (IM) is a rare finding in urinary bladder specimens. It is unclear whether IM without dysplasia is a precursor of malignancy in the urinary system. We retrospectively selected 9 cases of IM of bladder (1 case harboring high-grade dysplasia), and performed mutation analysis for genes frequently mutated in colon cancer including BRAF, APC, KRAS, MET, NRAS, PIK3CA, CTNNB1, FBXW7, and TP53 using validated clinical tests. Control groups included 7 colonic tubular adenomas, 10 high-grade papillary urothelial carcinomas. One IM case revealed an APC mutation and another showed an NRAS mutation. Among the tubular adenomas cases, 6 of 7 (85.7%) harbored KRAS mutations and 3 of 7 (42%) APC mutations. Among urothelial carcinomas cases, 1 revealed a KRAS mutation, 2 had PIK3CA mutations, and all cases were negative for APC mutations. Clinical follow-up for the IM patients was available with a median follow-up of 70 months. One patient-without any mutation in the genes investigated-developed invasive bladder adenocarcinoma with intestinal differentiation with metastasis to the liver and lung. Neither of the 2 patients harboring mutations developed any malignancy. In conclusion, a minority of cases with IM without dysplasia bear mutations in the genes commonly associated with colonic adenocarcinoma, suggesting a premalignant potential for such lesions possibly following the classic multistep chromosomal instability pathway of carcinogenesis. A larger cohort of patients with longer follow-up is needed to better establish whether close follow-up is warranted for mutation-harboring IM of the bladder.

Identifiants

pubmed: 31876604
doi: 10.1097/PAI.0000000000000812
pii: 00129039-202011000-00010
pmc: PMC9281533
mid: NIHMS1820758
doi:

Substances chimiques

APC protein, human 0
Adenomatous Polyposis Coli Protein 0
KRAS protein, human 0
BRAF protein, human EC 2.7.11.1
Proto-Oncogene Proteins B-raf EC 2.7.11.1
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

786-790

Subventions

Organisme : NCI NIH HHS
ID : T32 CA193145
Pays : United States

Références

Mod Pathol. 2017 Aug;30(8):1133-1143
pubmed: 28548125
JAMA Oncol. 2015 Apr;1(1):40-49
pubmed: 26182302
Hum Pathol. 2013 Sep;44(9):1890-4
pubmed: 23664485
Nat Rev Cancer. 2005 Sep;5(9):713-25
pubmed: 16110317
Cancer Res. 2010 May 1;70(9):3463-72
pubmed: 20406976
PLoS One. 2014 Sep 03;9(9):e106301
pubmed: 25184754
BJU Int. 2013 Nov;112 Suppl 2:27-31
pubmed: 24127673
Oncotarget. 2012 Dec;3(12):1566-75
pubmed: 23248156
Urology. 1997 Sep;50(3):427-31
pubmed: 9301710
Carcinogenesis. 2008 Mar;29(3):620-8
pubmed: 17893233
PLoS One. 2011 Apr 14;6(4):e18583
pubmed: 21533174
Histopathology. 2015 Sep;67(3):325-30
pubmed: 25640978
Nat Med. 2012 Feb 12;18(3):382-4
pubmed: 22327622
Clin Cancer Res. 2007 Oct 15;13(20):6232-6
pubmed: 17947491
Oncogene. 2014 Apr 24;33(17):2245-54
pubmed: 23708654
Genome Med. 2016 Jun 01;8(1):62
pubmed: 27245685
J Urol. 2003 Nov;170(5):1892-6
pubmed: 14532801
Nat Rev Cancer. 2001 Oct;1(1):55-67
pubmed: 11900252
Clin Cancer Res. 2009 Oct 1;15(19):6008-17
pubmed: 19789314
BMC Urol. 2016 Jun 07;16(1):24
pubmed: 27267922
Urology. 2008 May;71(5):915-8
pubmed: 18455631

Auteurs

Ali Amin (A)

Department of Pathology, Lifespan Academic Medical Center and Brown University, Providence, RI.

Belkiss Murati-Amador (B)

Departments of Pathology.

Kara A Lombardo (KA)

Departments of Pathology.
The Greenberg Bladder Cancer Institute of Johns Hopkins University, Baltimore, MD.

Cynthia L Jackson (CL)

Department of Pathology, Lifespan Academic Medical Center and Brown University, Providence, RI.

Zakaria Grada (Z)

Department of Pathology, Lifespan Academic Medical Center and Brown University, Providence, RI.

Doreen N Palsgrove (DN)

Departments of Pathology.

Andres Matoso (A)

Departments of Pathology.
Urology.
Oncology, The Johns Hopkins Medical Institutions.
The Greenberg Bladder Cancer Institute of Johns Hopkins University, Baltimore, MD.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH